Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Hideo Machimura"'
Autor:
Atsuko Mokubo, Masahiko Takai, Mizuki Kaneshiro, Takehiro Kawata, Akira Kanamori, Yasushi Tanaka, Tetsuo Takuma, Ikuro Matsuba, Akira Kubota, Mitsuo Obana, Shinichi Umezawa, Taisuke Kikuchi, Hideo Machimura, Hiroshi Takeda, Yoko Matsuzawa, Tetsuya Motomiya, Masahiro Takihata, Kotaro Iemitsu, Hajime Maeda, Masaaki Miyakawa, Shogo Ito, Yasuo Terauchi, Taro Asakura
Publikováno v:
Diabetes Technology & Therapeutics. 22:228-234
Background: Sodium/glucose cotransporter-2 (SGLT2) inhibitors improve glycemic control and reduce body weight by increasing glycosuria. Although a compensatory increase of food intake has been repo...
Autor:
Yasushi Tanaka, Ikuro Matsuba, Atsuko Mokubo, Sachio Aoyanagi, Yasuo Terauchi, Hikaru Amemiya, Hiroshi Takeda, Akira Kanamori, Nobuaki Minami, Akira Kubota, Hideaki Kaneshige, Shigeru Nakajima, Yoko Matsuzawa, Hideo Machimura, Kazuaki Shinoda, Takehiro Kawata, Takashi Iizuka, Tatsuya Saito, Mizuki Kaneshiro, Masahiko Takai, Keiji Tanaka, Taro Asakura, Masahiro Takihata, Fuyuki Minagawa, Mitsuo Obana, Masashi Ishikawa, Taisuke Kikuchi, Kazuhiko Hoshino, Kotaro Iemitsu, Nobuo Sasai, Shinichi Umezawa, Shogo Ito, Tetsuo Takuma, Masaaki Miyakawa
Publikováno v:
Journal of Clinical Medicine Research
Background: Ipragliflozin, a sodium-glucose transporter 2 inhibitor, was administered to patients with type 2 diabetes mellitus for 24 weeks to evaluate its effect on glycemic control and body composition. Methods: This was an investigator-initiated
Autor:
Takehiro Kawata, Takashi Iizuka, Taro Asakura, Fuyuki Minagawa, Hideo Machimura, Nobuo Sasai, Mizuki Kaneshiro, Akira Kanamori, Keiji Tanaka, Akira Kubota, Masaaki Miyakawa, Nobuaki Minami, Shigeru Nakajima, Taisuke Kikuchi, Shogo Ito, Hiroshi Takeda, Kazuaki Shinoda, Kotaro Iemitsu, Yasushi Tanaka, Yasuo Terauchi, Hikaru Amemiya, Masahiko Takai, Hideaki Kaneshige, Tatsuya Saito, Ikuro Matsuba, Yoko Matsuzawa, Mitsuo Obana, Sachio Aoyagi, Kazuhiko Hoshino, Masahiro Takihata, Atsuko Mokubo, Masashi Ishikawa, Shinichi Umezawa, Tetsuo Takuma
Publikováno v:
Journal of Clinical Medicine Research
Background: Ipragliflozin is a sodium-glucose co-transporter 2 inhibitor that can improve glycemic control and reduce body weight and blood pressure in patients with type 2 diabetes mellitus (T2DM). We evaluated the efficacy and safety of ipraglifloz
Autor:
Mitsuo Obana, Masaaki Miyakawa, Fuyuki Minagawa, Tetsurou Takuma, Atsuko Mokubo, Takehiro Kawata, Akira Kubota, Mizuki Kaneshiro, Yasuo Terauchi, Hajime Maeda, Kotaro Iemitsu, Yasushi Tanaka, Akira Kanamori, Masao Toyoda, Ikuro Matsuba, Hikaru Amamiya, Hiroshi Takeda, Masahiko Takai, Yoshikazu Naka, Hideaki Kaneshige, Daisuke Suzuki, Hideo Machimura, Masashi Ishikawa
Publikováno v:
Diabetology International. 5:98-104
Our goal was to evaluate liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in monotherapy and combination therapy for Japanese type 2 diabetes patients. Patients with type 2 diabetes (111 men, 83 women; mean age 57.6 ± 12.6 years) wer
Autor:
Akira Kanamori, Taro Asakura, Masahiko Takai, Masashi Ishikawa, Yasushi Tanaka, Nobuaki Minami, Akira Kubota, Nobuo Sasai, Hideo Machimura, Shigeru Nakajima, Ikuro Matsuba, Masaaki Miyakawa, Yasuo Terauchi, Hikaru Amemiya, Mizuki Kaneshiro, Kazuhiko Hoshino, Hideaki Kaneshige, Hiroshi Takeda, Tetsuro Takuma, Keiji Tanaka, Shinichi Umezawa, Kotaro Iemitsu, Sachio Aoyagi, Atsuko Mokubo, Shogo Ito, Mitsuo Obana, Taisuke Kikuchi, Takehiro Kawata, Takashi Iizuka, Masahiro Takihata
Publikováno v:
Journal of Clinical Medicine Research
Background: Ipragliflozin is a selective sodium glucose co-transporter 2 (SGLT2) inhibitor that blocks glucose reabsorption in the proximal tubules. SGLT2 inhibitors are expected to be effective in patients with insulin resistance and obesity, but it